Yamagishi SI

References (3)

Title : SMTP-44D alleviates diabetic retinopathy by suppressing inflammation and oxidative stress in in vivo and in vitro models - Ishibashi_2025_J.Pharmacol.Sci_157_57
Author(s) : Ishibashi M , Shibata K , Terasaki M , Saito Y , Yamagishi SI , Hasumi K , Nobe K
Ref : J Pharmacol Sci , 157 :57 , 2025
Abstract :
PubMedSearch : Ishibashi_2025_J.Pharmacol.Sci_157_57
PubMedID: 39828394

Title : SMTP-44D Inhibits Atherosclerotic Plaque Formation in Apolipoprotein-E Null Mice Partly by Suppressing the AGEs-RAGE Axis - Terasaki_2023_Int.J.Mol.Sci_24_6505
Author(s) : Terasaki M , Shibata K , Mori Y , Saito T , Matsui T , Ohara M , Fukui T , Hasumi K , Higashimoto Y , Nobe K , Yamagishi SI
Ref : Int J Mol Sci , 24 :6505 , 2023
Abstract :
PubMedSearch : Terasaki_2023_Int.J.Mol.Sci_24_6505
PubMedID: 37047475

Title : Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients - Tahara_2016_Curr.Vasc.Pharmacol_14_552
Author(s) : Tahara N , Yamagishi SI , Bekki M , Kodama N , Nakamura T , Sugiyama Y , Oshige T , Kumashiro Y , Honda A , Tahara A , Igata S , Fukumoto Y
Ref : Curr Vasc Pharmacol , 14 :552 , 2016
Abstract :
PubMedSearch : Tahara_2016_Curr.Vasc.Pharmacol_14_552
PubMedID: 27357182